Mission Statement, Vision, & Core Values (2026) of Joinn Laboratories(China)Co.,Ltd.

Founded in 1995, JOINN Laboratories Co., Ltd. has grown into a global CRO powerhouse with a presence across Beijing, Suzhou, Chongqing and Guangzhou and international sites in Richmond, CA and Worcester, MA, backed by a workforce of over 2,500 professionals and executives averaging 25 years of industry experience; the company's mission to "serve for drug innovation" and prioritize lifecycle safety assessments is reinforced by full-spectrum services from early R&D to clinical trials and pharmacovigilance, bolstered by top-tier certifications including GLP recognition from China's NMPA, the US FDA, Japan's PMDA, Korea's MFDS, OECD compliance and AAALAC accreditation-credentials that underpin a vision to lead in technical development and manufacture of all‑natural performance materials while living its core values of integrity, innovation, collaboration, responsibility and excellence; financially, JOINN's trajectory is tangible with a record ¥1.2 billion revenue in 2024, a 25% year‑over‑year increase, setting the stage for deeper international integration and expanded safety and innovation capabilities

Joinn LaboratoriesCo.,Ltd. (6127.HK) - Intro

• Founding year: 1995
• Employee base: >2,500 worldwide
• Executive team average experience: ~25 years in drug development and regulatory review
• Core service areas: non-clinical pharmacology, toxicology, clinical trials, pharmacovigilance, registration support

• Domestic facilities: Beijing, Suzhou, Chongqing, Guangzhou
• International sites: Richmond, California; Worcester, Massachusetts
• Quality and accreditation: GLP certifications from China NMPA, US FDA, Japan PMDA, Korea MFDS, OECD GLP; AAALAC accreditation

• Early-stage R&D support: pharmacology models, ADME, toxicology studies
• Preclinical development: GLP-compliant studies, safety pharmacology, repeat-dose toxicity
• Clinical development: phase I-III trial management, CRO operational execution
• Regulatory and post-market: registration dossier preparation, pharmacovigilance and safety monitoring

• Mission: To accelerate safe, high-quality drug development through integrated, GLP- and GCP-compliant research services that bridge innovation to regulatory approval.
• Vision: To be a global partner of choice for biopharma companies by delivering end-to-end R&D and regulatory solutions with scientific rigor and international quality standards.
• Core values: Scientific integrity, regulatory excellence, client partnership, continuous innovation, and operational transparency.

• Compliance breadth: Multijurisdictional GLP certifications enable studies acceptable to major regulatory agencies, reducing duplication and accelerating submissions.
• Integrated service model: Capability to move programs from discovery through clinical development and post-market safety under one project governance.
• Experienced leadership: Senior management with deep regulatory review and development experience supports strategic regulatory interactions and study design alignment.

Joinn LaboratoriesCo.,Ltd. (6127.HK) - Overview

Mission Statement: JOINN Laboratories' mission is to 'serve for drug innovation, focus on safety assessments and monitoring of drugs throughout life cycles.' This mission drives the company's core activities in preclinical safety assessment, regulatory toxicology, bioanalytical testing, and lifecycle pharmacovigilance to support biopharmaceutical innovation globally.

• Support for drug innovation through GLP-compliant preclinical safety studies, bioanalytical services, and CRO/CMO collaboration networks.
• Comprehensive safety assessments spanning acute, subchronic, chronic toxicity, reproductive and developmental toxicology, genotoxicity, and safety pharmacology.
• Lifecycle monitoring including post-market safety surveillance and ADME/Tox follow-up studies to inform risk management.
• Integration of global resources and capacity expansion to meet increasing demand from domestic and international sponsors.

How the mission translates into measurable capabilities and strategic priorities:

• Investment in GLP facilities and expansion of international service capacity - supporting local and multinational pharmaceutical clients.
• Quality and compliance focus: continued accreditation and adherence to international GLP and regulatory standards.
• Talent and R&D: hiring and training to expand toxicology, pathology, analytical chemistry, and data science teams.
• Strategic partnerships and service integration to shorten drug development timelines and de-risk clinical entry.

Operational priorities aligned with the mission:

• Enhance international service capabilities and regulatory alignment to attract global biopharma programs.
• Scale laboratory throughput while maintaining GLP compliance and data integrity.
• Invest in digital pathology, bioanalytical automation, and data management to improve turnaround and reporting quality.
• Leverage strategic collaborations to broaden service offerings from preclinical safety to lifecycle monitoring.

Relevant corporate context and further reading: Joinn Laboratories(China)Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Joinn LaboratoriesCo.,Ltd. (6127.HK) - Mission Statement

• Prioritize scalable, technically advanced production of natural-performance ingredients for pharmaceuticals, nutraceuticals, and specialty chemicals.
• Embed sustainability across the value chain: raw-material sourcing, low-impact processing, and waste minimization.
• Maintain rigorous quality systems (GMP, ISO) to support global regulatory compliance and export growth.
• Expand international service capabilities and integrate resources across global operations to better serve multinational customers.

• Innovation focus: advanced extraction, purification, formulation and process intensification to raise product performance metrics.
• Sustainability focus: substitution of petrochemical inputs with renewable, natural feedstocks and lower carbon manufacturing.
• Market focus: premium pharmaceutical intermediates, botanical actives for nutraceuticals, and specialty eco-friendly ingredients.

• Scientific rigor - evidence-based development and stringent quality controls.
• Sustainability - minimizing environmental footprint while maximizing natural sourcing.
• Customer-centricity - tailored technical service and regulatory support for global partners.
• Collaboration - cross-disciplinary R&D and global resource integration to accelerate scale-up.
• Integrity - transparent governance, compliance with GMP and global standards.

• Increase R&D intensity: target R&D-to-revenue ratio >9% within three years; focus on high-value botanical actives and novel extraction technologies.
• Capacity and footprint expansion: investments in new GMP facilities and modular plants to shorten customer qualification timelines.
• Internationalization: bolster overseas regulatory support, distribution partnerships, and local technical teams to grow export share above 40%.
• Sustainability roadmap: phased reduction of process emissions and water intensity with measurable targets tied to capital projects.

Joinn LaboratoriesCo.,Ltd. (6127.HK) - Vision Statement

• Integrity: Uphold transparency, compliance, and ethical conduct across R&D, clinical testing, and commercial operations.
• Innovation: Continuously invest in technology platforms, bioanalytical methods, and digitalization to shorten development timelines.
• Collaboration: Build strategic partnerships with biotech, CROs, and academic institutions to expand capabilities and reach.
• Responsibility: Minimize environmental footprint, promote laboratory safety, and support community health initiatives.
• Excellence: Exceed regulatory and client expectations through rigorous quality systems and certified processes.

• R&D intensity target: ≥10% of annual revenue reinvested into platform development and method validation.
• Quality target: Maintain regulatory compliance with CNMP, GLP, and ISO standards across key facilities; aim for zero major inspection findings.
• Geographic reach: Expand service footprint across China's first‑tier biotech hubs and selectively into APAC markets within three years.

• Integrity KPI: Regulatory inspection pass rate - target 100%; 2023 reported >98% pass rate across inspections.
• Innovation KPI: New assay/platform launches - 2023 saw 14 new validated methods and one automation platform rollout.
• Collaboration KPI: Strategic partnerships - 2023 signed 6 multi‑year agreements with biotech clients and academic centers.
• Responsibility KPI: Energy consumption reduction - 2023 achieved 7% energy intensity reduction vs. 2021 baseline.
• Excellence KPI: Client satisfaction Net Promoter Score (NPS) - 2023 NPS of +54 across core service lines.

• Board oversight: Dedicated ESG and Risk committees to monitor ethics, environmental performance, and research integrity.
• Operational accountability: Facility heads measured on safety, quality, and delivery KPIs tied to variable compensation.
• Transparency: Periodic public disclosures on financial, quality, and sustainability metrics aligned with investor expectations.